Scribe Collaborated with Prevail to Advance In Vivo CRISPR-based Genetic Therapies for Neurological and Neuromuscular Diseases
Shots:
- Scribe will receive a $75M up front and equity investment, ~$1.5B in development and commercial milestones & is also eligible to receive research funding along with royalties on net future sales
- Prevail, a wholly owned subsidiary of Lilly gets an exclusive right to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified targets for neurological and neuromuscular diseases. Scribe also get the right to opt-in to co-fund and share profits in the US on one program
- The collaboration combines Scribe’s novel CRISPR by Design approach with Prevail’s deep expertise to develop genetic medicines for neurological disorders towards specified genetic targets
Ref: Bussinesswire | Image: Scribe
Related News:- Sanofi Entered into a Research Collaboration with Scribe Therapeutics to Advance CRISPR-based Cell Therapies for Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
